Role of the BrafV637E Mutation in Hepatocarcinogenesis Induced by Treatment With Diethylnitrosamine in Neonatal B6C3F1 Mice

Masahiro Yamamoto,1 Hiroki Tanaka,2 Bing Xin,1 Yuji Nishikawa,1 Kosuke Yamazaki,3 Keiko Shimizu,2 and Katsuhiro Ogawa1*

1Department of Pathology, Asahikawa Medical University, Asahikawa, Japan
2Department of Forensic Medicine, Asahikawa Medical University, Asahikawa, Japan
3Department of Clinical Medicine, Surgery Area, Japanese Red Cross Hokkaido College of Nursing, Kitami, Japan

INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer death worldwide [1]. Many rodent hepatocarcinogenesis models have been developed to investigate the pathogenesis of HCC, to perform risk assessments of food/nutrition and to evaluate the effects of therapeutic agents. Diethylnitrosamine (DEN) is often used to induce hepatocarcinogenesis in rodents. Delivering a single low dose of DEN to neonatal mice results in the development of HCC without any further treatment [2]. In this model, foci of cellular alterations are observed in the early stage of hepatocarcinogenesis, and in the late stages, adenomas and HCC develop.

The mutational changes associated with chemically induced hepatocarcinogenesis depend not only on the carcinogens used but also on the species, strain, age and gender of the animals [3]. Buchmann et al. [4] have reported that in the hepatic tumors induced by neonatal treatment with DEN or 7, 12-dimethylbenz-(a)anthracene, the H-ras codon 61 mutation is more prevalent in hepatocarcinogenesis-susceptible strains such as C3H mice, whereas the BrafV637E mutation is more prevalent in resistant strains such as C57BL/6, indicating that either mutation may be selected depending on the genetic background.

The mouse BrafV637E mutation corresponds to the human BrafV600E mutation, which is frequently detected in certain human cancers, including melanoma and thyroid, ovarian and colon cancers [5]. In this study, we determined that the BrafV637E mutation is very common in hepatic lesions induced by neonatal DEN treatment in male B6C3F1 mice.
However, the frequency of the Braf mutation in hepatocarcinogenesis induced by agents other than DEN and the changes induced by the Braf mutation in hepatocytes, particularly with respect to intracellular signaling and gene expression, have not been well studied. We therefore investigated (i) whether this mutation is specific to the DEN-induced model, (ii) how the BrafV637E mutation might provide a selective advantage to the mutated cells, and (iii) whether liver-specific expression of mutated Braf using an albumin enhancer/promoter causes phenotypic changes resembling those of DEN-induced hepatic tumors.

MATERIALS AND METHODS

Carcinogenic Treatment

Male B6C3F1 mice, which are commonly used for DEN-induced hepatocarcinogenesis [2] and to assess the carcinogenicity of chemicals [6], were generated by mating female C57BL/6j and male C3H/HeJ mice (CLEA Japan, Tokyo, Japan). One group of mice was intraperitoneally injected with DEN at a dose of 5 μg/g body weight at 2 wk of age, and was fed a normal chow diet thereafter. The mice were sacrificed at 5, 8, and 13 months (Table 1). The second group was subcutaneously injected with CCl4 (1 ml/kg body weight) three times weekly beginning at 8 wk of age and was sacrificed at 6 months (Table 2). The third group was treated first with DEN (5 μg/g body weight) at 2 wk of age and then with intraperitoneal CCl4 injections twice weekly starting at 4 wk and was sacrificed at 6 months after the start of CCl4 treatment (Table 2). Spontaneous hepatic lesion samples isolated from 20-month-old male B6C3F1 mice were kindly provided by Dr. Takuji Tanaka (Tokai Cell Institute). Grossly visible tumors were isolated, frozen in liquid nitrogen and stored at −80°C until use. Microscopic foci were microdissected from 4-μm-thick paraffin sections using a 27-gauge needle under microscopic observation. Livers of age-matched untreated mice were used as controls. All experimental procedures performed on mice were approved by the Asahikawa Medical University animal experiment committee on the basis of the guidelines for the humane care and protection of animals.

Generation of Alb-Cre/BrafV600E Mice

Homozygous male BrafV600E mice (B6.129P2(Cg)-Braftm1Mmc > J) reported by Dankort et al. [7] were purchased from Jackson Laboratories (Bar Harbor, ME). In these mice, a LoxP-flanked cassette containing the human Braf exon 15–18 cDNA, mouse Braf polyadenylation sequences and neo gene is inserted into the mouse Braf intron 14 upstream of the human Braf exon 15 cDNA encoding the BrafV600E mutation. Alb-Cre/BrafV600E mice were produced by in vitro fertilization using heterozygous female Alb-Cre (Jackson Laboratories) and homozygous male BrafV600E mice. The hepatic expression of the transgene was investigated by RT-PCR and direct sequencing. Twenty male and 20 female Alb-Cre/BrafV600E mice were generated.

Whole-Exome Analysis

DNA was extracted from the DEN-induced hepatic tumors and age-matched normal liver samples and then purified using a DNeasy Blood and Tissue Kit (Qiagen, Netherlands). For hepatic tumors, nonparenchymal cells were removed before DNA extraction as follows: the livers containing the DEN-induced tumors were perfused with collagenase solution, and the tumors (5–10 mm in diameter) were removed, minced with scissors, and passed through a 100-μm cell strainer (BD Biosciences, San Jose, CA). The tumor cells were collected by low-speed centrifugation (90g for 1 min) and washed twice with phosphate-buffered saline (PBS). After a quality check of the DNA using a Qubit Fluorometer (Thermo Fisher Scientific, Wal-tham, MA), the exons were enriched by using an Agilent SureSelect Mouse All Exon kit (Agilent Technologies, Santa Clara, CA), and this was followed by sequencing on a HiSeq 2000 sequencer (Illumina, San Diego, CA). The mutations were analyzed within the exon regions with more than 100-fold coverage.

PCR or RT-PCR and Direct Sequencing

For grossly visible tumors, DNA was extracted from frozen materials with a DNeasy Blood and Tissue Kit. For microscopic foci, DNA was extracted from microdissected samples with a DEXPAT kit (Takara Bio, Japan). The nomenclature of microscopic foci followed the criteria of the International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice [8]. The region that included the Braf codon 637 was amplified by PCR using appropriate primers (forward: 5′-gacctcacggtaaaaataggtgac, reverse: 5′-gcaattatgcctggcttacaa) and Mighty Amp DNA Polymerase (Takara Bio). Total RNA was extracted from frozen liver tissues of normal C57BL/6j and Alb-Cre/BrafV600E mice with Sepasol (Nacalai Tesque, Japan) and was reverse-transcribed with a cDNA Synthesis Kit (Roche, Basel, Switzerland). The region that included the Braf codon 637 was amplified from the cDNA samples by PCR using primers (forward: 5′-accctcagtaaaataggtgc, reverse: 5′-gcaattatgcttgctcataa) and Mighty Amp DNA Polymerase (Takara Bio). The amplified DNA was cloned into pGEM-T easy vector (Promega, Madison, WI) and sequenced.

Molecular Carcinogenesis

| Age (months) | No. mice | Foci | Tumors |
|--------------|----------|------|--------|
| 5            | 7        | 16/18 (88.8%) | —      |
| 8            | 3        | 22/28 (78.5%) | —      |
| 13           | 3        | — | 16/17 (94.1%) |

*Histological type, not determined.
Kingdom) and sequenced using a BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific) on an Applied Biosystems 3500 Genetic Analyzer (Thermo Fisher Scientific).

Quantitative Real-Time PCR (qRT-PCR)
To quantify the p15Ink4b and p19Arf mRNA, RNA was extracted from DEN-induced hepatic tumors and age-matched normal livers. cDNA synthesized as described above was used in qRT-PCR reactions with incorporation of LightCycler RNA Master SYBR Green I (Roche) using the following primers: p15Ink4b, forward 5'-ccaatccaggtcatgatgat-3' and reverse 5'-cgtgcacaggtctggtaag-3'; p19Arf, forward 5'-gctctggctttcgtgaacat-3' and reverse 5'-tgagcagaagagctgctacg-3'. Samples were normalized to the levels of Gapdh mRNA quantified by qRT-PCR using the following primers: forward 5'-accacagtcacgccatcac-3' and reverse 5'-tccaccaccctgttgctgta-3'. To quantify the PCR products, a standard curve was created using the PCR products purified with a PCR purification kit (Qiagen), and the DNA concentration was measured with a NanoDrop 2000 spectrophotometer (Thermo Fischer Scientific).

Immunohistochemistry
Tissue sections were incubated with primary antibodies against complement C5/C5a (Abbiotec, San Diego, CA) or Ki-67 (Novus Biological, Littleton, CO), and this was followed by detection of antibody binding using a Vector-stain kit (Vector, Burlingame, CA). Tissue sections that were not incubated with the primary antibodies served as negative controls.

Immunoblot Analysis
DEN-induced tumor samples were lysed in RIPA buffer, and equal amounts of protein were separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The blots were probed with antibodies against phospho- and total ERK1/2 (Cell Signaling, Danvers, MA) and Akt (Cell Signaling), BraF600E (Ventana, Tucson, AZ), total BraF (Cell Signaling) and C5/C5a. As a loading control, α-tubulin was detected using anti-α-tubulin antibody (Santa Cruz, Santa Cruz, CA). Band images were acquired using ECL Prime Western Blotting Detection Reagent (GH Healthcare Life Sciences, Pittsburgh, PA) and by exposure of the membranes to X-ray films.

Cytokine/Chemokine Array
The expression of cytokines and chemokines was investigated in two DEN-induced hepatic tumors (13 months) and two age-matched normal livers with a Mouse Cytokine Antibody Array Panel A, with loading of 40 types of specific antibodies (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. The reactions were detected by chemiluminescence, and the density of the spots was quantified with ImageJ software and normalized to the positive and negative control spots on the membranes.

Statistical Analysis
Statistical analyses were performed using Student’s t-tests, the Mann–Whitney test or Fisher’s exact test by using Prism software (GraphPad, La Jolla, CA), and probability values less than 0.05 were defined as statistically significant.

RESULTS

BraFV637E Mutation in DEN-Induced Hepatic Tumors
Whole-exome analysis detected 98 mutations in the four tumors isolated from three mice 13 months after neonatal DEN treatment (Supplementary Table S1). Of these, 96 were missense mutations, one was a six-base deletion, and one was a one-base insertion. Six mutations were detected in all four tumors, three mutations in 3/4 tumors, seven mutations in 2/4 tumors, and 82 mutations in 1/4 tumors (Supplemental Table S1). DEN induces G:C (C:G) to A:T (T:A) transitions via O6-ethyl guanine and T:A (A:T) to C:G (G:C) transitions via O4-ethyl thymine adducts [9]. In the present study, 47 of 96 (48.9%) base change mutations were attributed to O6-ethyl guanine or O4-ethyl thymine adducts. Although not attributable to O6-ethyl guanine or O4-ethyl thymine adducts, 38/96 (39.5%) base change mutations, including the BraFV637E mutation (GTG to GAG), were T:A to A:T transversions, which have been reported to be one of three types of the H-ras codon 61 mutations (wild type CAA to AAA, CGA or CTA) in mouse hepatic tumors induced by neonatal treatment with DEN [9].

The A:T to T:A transversion at the 2nd base of codon 637 in the Braf gene, which causes a valine to glutamic acid substitution (BrAFV637E), was detected in all four tumors (Supplemental Table S1). Importantly,
However, no mutations were detected in other known oncogenes or tumor suppressor genes. We then investigated the \textit{Bra}fV637E mutation in 17 hepatic tumors isolated from the three mice 13 months after DEN treatment. The \textit{Bra}fV637E mutation was detected in 16 (including the 4 samples used for the whole-exome analysis above) of 17 tumors by PCR/direct sequencing (Table 1). Because the \textit{H}-ras codon 61 mutation is frequently observed in DEN-induced mouse liver tumors [10, 11], we investigated the mutations in codons 12, 13, and 61 of the \textit{H}-ras, \textit{K}-ras and \textit{N}-ras genes, respectively, in the above 17 tumors. However, other than one \textit{K}-rasG13D mutation in one of the \textit{Bra}f mutated tumors, no mutations in these codons were detected in the samples (data not shown).

\textbf{\textit{Bra}fV637E Mutation in Microscopic Lesions}

We next addressed whether the \textit{Bra}fV637E mutation is also common in early DEN-induced lesions. Foci of altered cells were microdissected from the tissue sections from the livers at 5 and 8 months, and the \textit{Bra}f mutation was investigated by the PCR direct sequencing method (Figure 1A and B). At 5 months, 16/18 (88.8%) of the foci contained the \textit{Bra}fV637E mutation, and at 8 months, 22/28 (78.5%) foci contained the mutation (Table 1); however, the \textit{Bra}fV637E mutation was not observed in the non-tumor areas of the same sections (Figure 1B). Therefore, the \textit{Bra}fV637E mutation was equally frequent in the hepatic lesions at 5 and 8 months as at 13 months.

Foci of cellular alteration are classified into subtypes (basophilic, acidophilic, mixed cell, clear and amphophilic) [8], and we therefore investigated the types of lesions that contained the \textit{Bra}fV637E mutation. Of 45 foci investigated for the \textit{Bra}fV637E mutation, 37 were basophilic, and 8 were eosinophilic. Thirty-six of 37 basophilic foci (97.3%) had the \textit{Bra}fV637E mutation, whereas only 1 of 8 (12.5%) eosinophilic foci contained the \textit{Bra}fV637E mutation (basophilic vs. eosinophilic foci: $P < 0.0001$) (Figure 1C3).

\textbf{\textit{Bra}fV637E Mutation in Spontaneous Hepatic Tumors and in CCl4- or DEN/CCl4-Induced Hepatic Tumors}

We next explored whether the \textit{Bra}fV637E mutation is specific to DEN-induced hepatic tumors. For this purpose, the mutation was investigated in spontaneous hepatic lesions and in CCl4- or DEN/CCl4-induced hepatic tumors in male B6C3F1 mice. None of the 8 spontaneous hepatic lesions (6 foci and 2 HCCs) and none of the 24 CCl4-induced hepatic tumors had the mutation, whereas 5/7 (71.4%) of the DEN/CCl4 tumors had the \textit{Bra}fV637E mutation (Table 2). The difference in the frequency of the \textit{Bra}fV637E mutation between DEN and spontaneous or CCl4 lesions was statistically significant ($P < 0.0001$), whereas the difference between DEN and DEN/CCl4 lesions were not ($P = 0.3020$).

\textbf{Activation of Intracellular Signaling}

We investigated whether the \textit{Bra}fV637E mutation might activate the downstream ERK1/2 pathway in DEN-induced hepatic tumors. Weak phosphorylation of both ERK1/2 was detected in age-matched normal liver tissue, whereas prominent phosphorylation of ERK1 was observed in DEN-induced tumors isolated 13 months after DEN treatment (Figure 2). Because the PI3K/Akt pathway plays an important role in hepatocarcinogenesis [12–14] and because PI3K/Akt activation can reverse mutated \textit{Bra}f oncogene-induced senescence (OIS) [15], we investigated Akt phosphorylation in the DEN-induced hepatic tumors. The phosphorylation of Akt at S473 was increased in the hepatic tumors, whereas phosphorylation at T308 was weakly detected in normal livers but not in hepatic tumors (Figure 2).

\textbf{Expression of Cell-Cycle Regulators}

The mutational activation of \textit{Bra}f leads to OIS, which is characterized by the overexpression of cell-cycle regulators and may prevent cellular proliferation and induce a cellular senescence phenotype and/or apoptosis [16–18]. We therefore addressed whether the DEN-induced hepatic tumors exhibit OIS by investigating the expression of p15nk4b and p19arf, which play important roles in cell-cycle arrest in mouse cells [19–20]. Quantitative RT-PCR revealed that p15nk4b and p19arf mRNAs were increased in DEN-induced hepatic tumors isolated at 13 months after DEN treatment, whereas no signals for p19arf and p15nk4b mRNAs were detected in the age-matched normal livers after 35 cycles of PCR (Figure 3A and B).

\textbf{Overexpression of Pro-Proliferative/Pro-Survival Cytokines/Chemokines in DEN-Induced Hepatic Tumors}

OIS may lead to the senescence-associated secretory phenotype, which is characterized by the increased production of cytokines/chemokines that facilitate cell cycle arrest, apoptosis and immunosurveillance [21, 22]. We, therefore, investigated cytokine/chemokine expression in two DEN-induced hepatic tumors 13 months after DEN treatment and in two age-matched normal livers by using a mouse array with antibodies specific to 40 types of cytokines/chemokines. As shown in Figure 4A and B, the expression of complement C5/C5a, intercellular adhesion molecule-1 (ICAM-1), interleukin 1 receptor antagonist (IL-1ra) and chemokine CXCL9 was increased among the 40 factors specifically associated with hepatic tumors, whereas there were no significant differences in the expression levels of other factors between the tumors and age-matched normal livers. The expression of ICAM-1 [23], IL-1ra [24] and CXCL9 [25] has previously been reported in DEN-induced hepatic tumors; however, C5/C5a expression has not been reported. We therefore investigated C5/C5a expression in the hepatic lesions 5 and 8 months.
after DEN treatment by immunohistochemistry. Although the surrounding non-tumor hepatocytes exhibited diffuse/weak cytoplasmic staining for C5/C5a, the cells in the foci displayed strong staining in the cytoplasm, presumably in the rough endoplasmic reticulum and Golgi apparatus compartments (Figure 4C and inset). No staining was observed when the primary antibody was omitted (data not shown).

Characteristics of the Liver of Alb-Cre/BrafV600E Mice

Alb-Cre/BrafV600E mice were normal at birth, but started to die 8 wk after birth. We sacrificed the surviving animals during the period between 8 and
12 wk after birth. The livers of Alb-Cre/BrafV600E mice expressed mRNA derived both from normal mouse and mutated human Braf exon 15 (Figure 5A and B). The transgenic mice exhibited a 20% decrease in body weight compared with age-matched normal mice, but showed a fivefold-increase in the liver/body weight (Figure 5C, D, and E). Histological examination revealed that the liver consisted entirely of basophilic hepatocytes resembling basophilic foci at 8 wk of birth, and bile duct cells were further increased at 10–12 wk (Figure 5F1-3). The Ki-67 labeling index of hepatocytes in the Alb-Cre/BrafV600E mice was 3 times higher than that in normal mice (Figure 5G). Immunoblot analysis revealed that the livers of Alb-Cre/BrafV600E mice expressed the BrafV600E protein and showed hyperphosphorylation of ERK1 and AktS473 in a manner similar to that observed in DEN-induced hepatic tumors (Figure 6). Furthermore, immunohistochemical staining detected increased C5/C5a expression in the hepatocytes of Alb-Cre/BrafV600E mice (Figure 7A). In immunoblot analysis, although C5 levels were not different between age-matched normal and Alb-Cre/BrafV600E mice, a band with a smaller molecular weight probably corresponding to C5a was specifically detected in Alb-Cre/BrafV600E livers (Figure 7B). There was no difference in hepatic phenotype between male and female Alb-Cre/BrafV600E mice.

**DISCUSSION**

Whole-exome analysis of four DEN-induced hepatic tumors at 13 months detected 98 mutations; however, with the exception of the BrafV637E mutation, no known oncogene or tumor suppressor gene mutations were observed. PCR-direct sequencing of additional DEN-induced lesions, including microscopic foci and grossly visible tumors, revealed that 54/63 (85.7%) lesions had the BrafV637E mutations. Although some mutations might be passenger mutations, other mutations, particularly those detected in two or more tumors, might function as oncogenic drivers. In the hepatocarcinogenesis model induced by neonatal DEN treatment, individual DEN-induced tumors grow at different rates, and only a small fraction of preneoplastic lesions eventually progress to HCC [2]. Therefore, it is possible that some mutations may contribute to tumor progression in cooperation with the BrafV637E mutation.

The BrafV637E mutation was not detected in the spontaneous and CCl4-induced tumors but was detected in the tumors induced by neonatal DEN treatment followed by repeated CCl4 treatment, suggesting that the mutation was dependent on the genotoxic action of DEN. Further supporting this conclusion, 47/96 (48.9%) of the base-change mutations detected by whole-exome analysis were attributable to O6-ethyl guanine and O4-ethyl thymine, mutagenic adducts generated by DEN [9]. O6-ethyl guanine can form a G:T mismatch pair instead of a G:C pair, leading to the A:T (T:A) transition, whereas O4-ethyl thymine can mismatch with guanine instead of adenine, leading to the T:A (A:T) transition [9]. Furthermore, although not attributable to O6-ethyl guanine or O4-ethyl thymine, 38/96 (39.5%) of the base-change mutations, including the BrafV637E mutation (GTTG to GAG), were T:A (A:T) to A:T (T:A) transversions. The A:T to T:A transversion has been detected as one of three types of the H-ras codon 61 mutations (wild-type CAA to CTA).
Figure 4. A: The cytokine/chemokine array analysis used a membrane to load the antibodies individually against 40 types of mouse cytokines/chemokines. Four factors (1: C5/C5a, 2: ICAM-1, 3: CXCL9, 4: IL-1ra) were increased in hepatic tumors compared with normal livers. +: positive control, -: negative control. B: Densitometric analysis of the above data. The data represent the average values for two normal livers and two DEN-induced hepatic tumors. C: Immunohistochemical staining for C5/C5a in the focus (T) and in the surrounding non-tumor hepatic tissue (NT) (left). Inset: high magnification of the focus cell.
Figure 5. Alb-Cre/BrafV600E mice. A: RT-PCR primers (arrows) targeting mutated human and normal mouse Braf exon 15. B: The mutated (A) and normal bases (T) in Alb-Cre/BrafV600E mice (arrow in the right panel). C: Livers of normal and Alb-Cre/BrafV600E mice (C). D: Body weight of normal (n: 10 males, 10 females) and Alb-Cre/BrafV600E mice (n: 20 males, 20 females). E: Liver weight relative to body weight in normal (n: 10 males, 10 females) and Alb-Cre/BrafV600E mice (n: 20 males, 20 females). *P < 0.01. F: Histology of the liver in normal (F1) and Alb-Cre/BrafV600E mice at 8 wk (F2) and 12 wk after birth (F3). Scale bars: 50 μm. G: The Ki-67 labeling index of hepatocytes in normal (n = 5) and Alb-Cre/BrafV600E mice (n = 6). *P < 0.05.
in DEN-induced mouse hepatic tumors, together with the CAA to AAA (not attributable to O6-ethyl guanine or O4-ethyl thymine) and CAA to CGA mutations (attributable to O4-ethyl thymine) [9]. Thus, the Braf V637E mutation (GTG to GAG) may be generated by an unknown mechanism similar to that resulting in the H-ras codon 61 CAA to CTA mutation.

The Braf V637E mutation may lead to activation of the MAPK pathway. In the present study, although total ERK1/2 protein levels did not differ between normal livers and hepatic tumors, phosphorylation of ERK1 was increased in hepatic tumors, whereas both ERK1/2 were weakly phosphorylated in normal livers. Although the exact mechanism of hyperphosphorylation of ERK1 remains unclear, ERK1 may play a primary role in the activation of MAPK pathway. On the other hand the phosphorylation of Akt at S473 was increased in the hepatic tumors. Activation of the PI3K/Akt pathway has been reported to reverse OIS caused by the Braf mutation [15], and thus Akt activation may play a significant role in DEN-induced hepatocarcinogenesis. Although the mechanism of Akt phosphorylation requires further investigation, an unknown signaling pathway linked to the BrafV637E mutation and/or the autocrine factors generated by the hepatic tumor cells may play a role, as discussed below.

The mRNAs of p15Ink4b and p19Arf were detected in the hepatic tumors, but not in normal livers, suggesting that the BrafV637E mutation activates the OIS-signaling pathways along with pro-proliferative/survival pathways. We have previously demonstrated that the cyclin-dependent kinase inhibitor p27\textsuperscript{kip1} is overexpressed in DEN-induced hepatic tumors and that the BrdU labeling index is quite low in early tumors, indicating a slow rate of proliferation [12]. Because grossly visible tumors are not usually observed until 6–8 months after treatment with DEN in our experimental model, the growth of BrafV637E-mutated cells may be suppressed for a long period. Cyclin-dependent kinase inhibitors, such as p15\textsuperscript{ink4b}, p19\textsuperscript{Arf}, and p27\textsuperscript{kip1}, may counteract the BrafV637E-induced pro-proliferative signals, contributing to the dormancy of BrafV637E-mutated cells.

Cytokines/chemokines that participate in sustained cell proliferation, insensitivity to apoptosis and escape from immnosurveillance in cancer, such as C5/C5a, ICAM-1, IL-1ra, and CXCL9, were increased in the DEN-induced hepatic tumors, whereas factors that promote OIS, such as IL-1\alpha, β, IL-6, INF\gamma, and TNF\alpha [21,22] were not increased. Kang et al. [26] have reported that introduction of the N-rasG12V mutation into mouse hepatocytes in vivo leads to OIS, which in turn causes the OIS-induced secretory phenotype. The chemokines and cytokines such as CTACK, IL-1α, leptin, MCP1, and RANTES generated by N-rasG12V expressing hepatocytes recruit inflammatory cells that contribute to clearance of the N-rasG12V expressing hepatocytes. In the present study, however, we did not observe any inflammatory response against preneoplastic/neoplastic hepatocytes, and thus it is possible that the lesions that we investigated might have
somehow escaped from the inflammatory attack in an early stage. C5a, a C5 convertase-cleaved product of C5, activates the PI3K-Akt pathway via its receptor C5aR, which is involved in various tumor phenotypes, including cell proliferation, insensitivity to apoptosis, angiogenesis and escape from immunosurveillance [27,28]. Furthermore, C5-deficient mice exhibit impaired liver regeneration after partial hepatectomy [29]. ICAM-1 is overexpressed in DEN-induced rat hepatic tumor cells [23] and in human HCC cells [30], and levels of the secreted form sICAM-1 are increased in the serum of HCC patients [31,32]. ICAM-1 promotes metastasis via cell/cell and cell/extracellular matrix adhesion in cancer cells [33], and sICAM-1 is thought to inhibit the interaction between tumor cells and immune cells, enabling escape from immunosurveillance [34]. Our group has previously demonstrated overexpression of IL-1ra, which antagonizes the functions of IL-1α, β, in DEN-induced hepatic tumors [24], and an increase in IL-1ra over IL-1α, β contributes to tumor growth [35,36]. CXCL9 is reportedly upregulated in livers containing DEN-induced hepatic tumors in mice [25], and CXCL9 is excreted by tumor cells and subsequently recruits immune cells that express its receptor (CXCR3) towards the tumors. However, the CXCL9-CXCR3 interaction can attenuate tumor immunity and produce pro-tumorigenicity, depending on the tumor type [37]. Furthermore, CXCL9 directly promotes invasion/infiltration via CXCR3 on HCC cells in vitro [38]. In addition, our previous studies, together with those of other groups, have demonstrated that DEN-induced hepatic tumor cells produce a number of growth factors, such as TGF-α [39], insulin-like growth factor II [40], VEGF [13] and NGF [41]. Thus, the autocrine pro-proliferative/survival factors produced by the hepatic tumor cells may provide a selective advantage by accumulating within the tumor microenvironment. Additional studies are needed to clarify the relevance of autocrine factors to the BrafV637E mutation.

The transgenic mice expressing human BrafV600E, which corresponds to mouse BrafV637E, in the liver under control of the albumin/enhancer/promoter exhibited a 5-fold increase in liver/body weight ratio, and the liver consisted entirely of small basophilic hepatocytes mimicking those observed in basophilic foci induced by DEN. Furthermore, the liver exhibited hyperphosphorylation of ERK1 and AktS473 and increased expression of C5/C5a. Thus, the expression of BrafV637E protein is sufficient to induce the hepatocytic changes observed in DEN-induced hepatic tumors. However, the Alb-Cre/BrafV600E mice started to die 8 wk after birth, and most died by 12 wk. A similar phenomenon has previously been reported for the transgenic mice with liver-specific H-ras expression under control of the albumin enhancer/promoter [42]. The possibility that aberrant activation of Braf, and presumably also H-ras, in the liver causes fatal systemic disease(s) is now under investigation in our laboratory.

ACKNOWLEDGMENTS

This study was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology and grants from the Asahikawa Medical University Advanced Science Research Program. We are grateful to Dr. Takuji Tanaka of the Tokai Cell Institute for providing spontaneous mouse hepatic tumor samples.

REFERENCES

1. Mittal S, Seraq EL. Epidemiology of hepatocellular carcinoma. J Clin Gastroenterol 2013;47:S2–S6.
2. Vesselinovitch SD, Mihailovich N, Rao KV. Morphology and metastatic nature of induced hepatic nodular lesions in C57BL x C3H F1 mice. Cancer Res 1978;38:2003–2010.
3. Maronpot RR, Fox T, Malarey DE, Goldsworthy TL. Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 1995;101:125–156.
4. Buchmann A, Karcier Z, Schmid B, Strathmann J, Schwarz M. Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis. Mutat Res 2008;638:66–74.
5. Pakneshan S, Salajegheh A, Smith RA, Lam AK-Y. Clinico-pathological relevance of BRAF mutations in human cancer. Pathology 2013;45:346–356.
6. Huff JE, McConnell EE, Haseman JK, et al. Carcinogenesis studies: Results of 398 experiments on 104 chemicals from the U.S. National Toxicology Program. Ann N Y Acad Sci 1988;534:1–30.
7. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21:379–384.
8. Thoelen B, Maronpot RR, Harada T, et al. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol 2010;38:55S–81S.
9. Verna L, Whyssner J, Williams GM. N-nitosodimethylamine mechanistic data and risk assessment: Bioactivation, DNA-adduct formation, mutagenicity, and initiation. Pharmacol Ther 1996;71:57–81.
10. Buchmann A, Bauer-Hofmann R, Mahr J, Drinkwater NR, Luz A, Schwarz M. Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: Correlation with susceptibility to hepatocarcinogenesis. Proc Natl Acad Sci USA 1991;88:911–915.
11. Dragani TA, Manenti G, Colombo BM, et al. Incidence of mutations at codon 61 of the Ha-ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis. Oncogene 1996;16:333–338.
12. Yamamoto M, Tamakawa S, Yoshie M, Yaginuma Y, Ogawa K. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog 2006;45:901–913.
13. Tanaka H, Yamamoto M, Hashimoto N, et al. Hypoxia-independent overexpression of hypoxia-inducible factor 1 as an early change in mouse hepatocarcinogenesis. Cancer Res 2006;66:11263–11270.
14. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972–1983.
15. Vredeveld LCW, Possik PA, Smit MA, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation.
16. Dhomen N, Reis-Filho JS, Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009;15:294–303.

17. Michaloglou C, Vredeveld L, Soengas M, et al. BRAFV600E- associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720–724.

18. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006;6:472–726.

19. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the tumor suppressor p19ARF. Cell 1997;91:649–659.

20. Latres E, Malumbres M, Sotillo R, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 2000;19:3496–3506.

21. Bartek J, Hodny Z, Lukas J. Cytokine loops driving senescence. Nat Cell Biol 2008;10:1–3.

22. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland J. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest 2013;123:966–972.

23. Matsuoka S, Matsumura H, Arakawa Y, et al. Expression of intercellular adhesion molecule-1 in the livers of rats treated with diethylnitrosamine. J Clin Biochem Nutr 2009,45:137–143.

24. Yamada Y, Karasaki H, Matsushima K, Lee GH, Ogawa K. Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis. Lab Invest 1999;79:1059–1067.

25. Schneider C, Teuvel A, Yevsa T, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012;61:1733–1743.

26. Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of hepatocellular carcinoma through up-regulation of PREX2. J Mol Histol 2014;45:689–696.

27. Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta 2013;1836:287–295.

28. Lan X, Xiao F, Ding Q, et al. The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2. J Mol Histol 2014;45:689–696.

29. Rundhaug JE, Fischer SM. Role of intracellular interleukin-1 receptor antagonist in skin carcinogenesis. Mol Carcinog 2001;30:218–223.

30. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13:323–340.

31. Zührens G, Armbrecht T, Pirzer U, Meyer zum Büschenfelde KH, Ramadori G. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: Relationship to disease activity and cirrhosis. Hepatology 1993;18:798–802.

32. Shimizu Y, Minemura M, Tsuchishiro T, et al. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 1995;22:525–531.

33. Hayes SH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. Int J Clin Exp Pathol 2009;2:553–560.

34. Wilkowska AM, Borawksa MH. Soluble intercellular adhesion molecule-1 (sICAM-1): An overview. Eur Cytokine Netw 2004;15:91–98.

35. La E, Rundhaug JE, Fischer SM. Role of intracellular interleukin-1 receptor antagonist in skin carcinogenesis. Mol Carcinog 2001;30:218–223.

36. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989;4:715–724.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher’s web-site.